Updates: Salesforce and Revolution Medicines
Companies report increased use of AI tools and disclose executive share plans.
RVMD Health Care · 3 analyses · 4 expectations tracked
Insider tracks 4 open management expectations for this company. 3 insider sales recorded. Its latest periodic filing added 47 new risk factors.
Companies report increased use of AI tools and disclose executive share plans.
Revolution Medicines announced its financial results for the third quarter of 2026. It reported $197.6 million in net product revenue for RASONQUE and a net loss of $407.5 million. These are the company's first quarterly figures since receiving FDA approval for RASONQUE in late August 2026.
Revolution Medicines, Inc. drew a Tranche A loan of $250.0 million under its senior secured credit facility on October 8, 2026, paying a one‑time draw fee of $5.0 million after FDA approval of RASONQUE™.
Revolution Medicines, Inc.: 12 recorded developments from 10 official sources in 2026-10.
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC
| Latest | Earlier | Change | |
|---|---|---|---|
| Revenue quarter | $198M | $0 | — |
| Operating income quarter | −$373M | −$315M | -18.4% |
| Net income quarter | −$407M | −$305M | -33.5% |
| Diluted EPS quarter | −$1.90 | −$1.61 | -18.0% |
| Operating cash flow year to date | −$1.2B | −$624M | -85.6% |
| Cash and cash equivalents balance | $616M | $384M | +60.5% |
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $M
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Revolution Medicines, Inc. RVMD | $198M | — | -188.9% |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
The company expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design.
Not yet checked against later reports.
The company remains on track to initiate a first-in-human clinical trial evaluating RM-055.
Not yet checked against later reports.
Initial readout for the RASolve 301 trial is anticipated in 2027.
Not yet checked against later reports.
All sites in the RASolve 301 trial are expected to close enrollment by the end of November 2026.
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|---|---|---|---|---|---|
| November 16, 2026 | Stephen Kelsey | Planned sale 10b5-1 plan | 108,640 | — | $18,717,586 | SEC |
| November 11, 2026 | Jack Lee Anders | Planned sale 10b5-1 plan | 35,750 | — | $6,901,895 | SEC |
| November 11, 2026 | Jack Anders | Sale 10b5-1 plan | 35,750 | $188.10 | $6,724,688 | SEC |
| November 9, 2026 | Anthony Mancini | Sale 10b5-1 plan | 811 | $200.00 | $162,200 | SEC |
| October 26, 2026 | Anthony Mancini | Sale 10b5-1 plan | 2,310 | $186.99 | $431,947 | SEC |
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| Fidelity (FMR) | 15,397,714 | $3,160,534,467 | +26.2% | Q3 2026 |
| BlackRock | 13,857,324 | $2,844,354,468 | +1.2% | Q3 2026 |
| State Street | 5,063,861 | $1,039,408,109 | +3.4% | Q3 2026 |
| Geode Capital Management | 4,007,450 | $832,063,384 | +1.6% | Q3 2026 |
| Wellington Management | 3,130,941 | $642,656,949 | -18.5% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 2,157,479 | $404,052,667 | — | Q2 2026 |
| Citadel Advisors | 1,310,983 | $269,092,370 | +122.2% | Q3 2026 |
| Two Sigma Investments | 91,592 | $18,800,174 | -87.6% | Q3 2026 |
| Millennium Management | 81,236 | $16,674,501 | -62.4% | Q3 2026 |
| D. E. Shaw & Co. | 766,324 | $8,782,073 | -51.9% | Q3 2026 |
| Renaissance Technologies | 6,200 | $602,950 | — | Q1 2026 |
| T. Rowe Price | 1,977,484 | $405,899 | -17.3% | Q3 2026 |
| Duquesne Family Office (Stanley Druckenmiller) | 436,287 | $89,552 | +9.2% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.